Mr David Hoey

David Hoey

Mr. Hoey has extensive experience relevant to our Company, with more than 25 years’ experience in technology financing and commercialization. Mr. Hoey is a US-based director and his primary expertise is in business development, strategic planning, market development, corporate partnering and financings for medical technologies, diagnostics and drug development. His skills and experience are invaluable to the ongoing commercialization and launch of the Company’s products, especially in the United States.

Mr. Hoey has served as a non-executive director since March 2016 and has been a member of the Audit & Compliance Committee since that date. Mr. Hoey has served as a member of the Remuneration & Nomination Committee between June 21, 2016 and September 21, 2017.

Mr. Hoey is currently Chief Executive Office and a director of Vaxxas, Inc., a company which has developed and is commercializing a novel vaccine delivery technology – The NanopatchTM. He also serves as an advisor to Healthcare Ventures LLC. During his career Mr. Hoey has worked in management and leadership roles in the preclinical development of small molecule and biologic therapeutics, molecular diagnostic assays and platforms, and analytical instrumentation. Mr. Hoey served as vice president of business development at PathoGenetix, Inc., a company pioneering single molecular detection technologies for biodefence, clinical, and industrial applications.